How the SOX2 gene and 3D DNA shape drive squamous cancers

SOX2 acts in the 3D genome of squamous cancer

NIH-funded research Utah State Higher Education System--University of Utah · NIH-11250133

Researchers will map how the SOX2 gene and the three-dimensional folding of DNA promote squamous cancers to point toward new treatment targets for people with tumors of the skin, lung, esophagus, cervix, or upper digestive tract.

Quick facts

Grant typeR37 grant
Study typeNIH-funded research
Funding institutionUtah State Higher Education System--University of Utah NIH-funded
Lab location1 site (Salt Lake City, United States)
Project IDNIH-11250133 on NIH RePORTER

What this research studies

This project looks at how SOX2 is switched on and controls other genes by studying the 3D folding of DNA that brings distant regulatory regions together. Scientists will use genomic mapping methods on tumor samples and laboratory models to find the enhancer regions and protein partners that loop to the SOX2 gene. They will test whether disrupting those loops or the interacting factors can block cancer cell growth. The team aims to identify more drug-friendly targets or biomarkers because SOX2 itself is hard to target directly.

Who could benefit from this research

Good fit: People with squamous cell carcinomas (for example of the lung, esophagus, skin, cervix, or upper digestive tract), especially tumors known to overexpress SOX2, would be most relevant to this research.

Not a fit: Patients with non-squamous cancers or tumors that do not express SOX2 are unlikely to benefit directly from findings focused on SOX2-driven mechanisms.

Why it matters

Potential benefit: If successful, the work could reveal new drug targets or biomarkers that lead to more precise, less invasive treatments for patients with SOX2-driven squamous cancers.

How similar studies have performed: Previous laboratory studies have linked SOX2 to squamous cancers but directly targeting SOX2 has been difficult, and studying 3D genome interactions is a newer approach with promising preclinical signals.

Where this research is happening

Salt Lake City, United States

Researchers

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page below.
Last reviewed 2026-06-13 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.